Oncolytics Biotech INC 8-K Filing
Ticker: ONCY · Form: 8-K · Filed: Apr 6, 2026 · CIK: 0001129928
Sentiment: neutral
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 9.8 · Accepted 2026-04-06 09:24:53
Filing Documents
- oncy-20260406.htm (8-K) — 29KB
- oncolyticsfdascacmeetingpr.htm (EX-99.1) — 13KB
- 0001129928-26-000024.txt ( ) — 158KB
- oncy-20260406.xsd (EX-101.SCH) — 2KB
- oncy-20260406_lab.xml (EX-101.LAB) — 21KB
- oncy-20260406_pre.xml (EX-101.PRE) — 12KB
- oncy-20260406_htm.xml (XML) — 3KB
01. Other Events
Item 8.01. Other Events. On April 6, 2026, Oncolytics Biotech, Inc. (the "Company") issued a press release announcing its upcoming Type C meeting with the U.S. Food and Drug Administration ("FDA") to discuss plans for a single-arm pivotal study for pelareorep and a checkpoint inhibitor in squamous cell anal carcinoma ("SCAC"). A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated into this Item 8.01 by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release issued by Oncolytics Biotech, Inc., dated as of April 6 , 2026 . 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: April 6, 2026 ONCOLYTICS BIOTECH, INC. By: /s/ Kirk Look Name: Kirk Look Title: Chief Financial Officer